<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00399308</url>
  </required_header>
  <id_info>
    <org_study_id>P001-001-B</org_study_id>
    <nct_id>NCT00399308</nct_id>
  </id_info>
  <brief_title>Evaluation of Safety and Activity of Celaderm in Healing Venous Leg Ulcers</brief_title>
  <official_title>An Initial Evaluation Of The Safety And Activity Of Celaderm(TM) Treatment Regimens In Healing Venous Leg Ulcers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shire Regenerative Medicine, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shire Regenerative Medicine, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This pilot study was designed to test the safety of Celaderm(TM) in treating venous leg
      ulcers and to give preliminary information about the efficacy of two different Celaderm(TM)
      dosing regimens.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Celaderm(TM) weekly for four weeks or biweekly for four treatments combined with Profore(R)
      compression vs. Profore(R) compression alone.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2007</start_date>
  <completion_date type="Actual">April 2008</completion_date>
  <primary_completion_date type="Actual">April 2008</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary Efficacy: Cumulative Proportion of Patients Completely Healed by the End of the Treatment Period, as Judged by the Investigator's Direct Observation.</measure>
    <time_frame>12 weeks</time_frame>
    <description>The primary efficacy observation was the proportion of wounds that achieved complete wound closure after 12 weeks of active treatment (i.e. of of Week 15 including screening/wash-in phase.)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Secondary Efficacy: Proportion of Patients Achieving 90% Re-epithelialization After 12 Weeks of Active Treatment.</measure>
    <time_frame>12 Weeks</time_frame>
    <description>Re-epithelialization was judged by the Medical Monitor based upon computerized planimetry of serial wound photographs.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary Efficacy: Durability of Wound Closure Through 12 Weeks After the End of the Treatment Period.</measure>
    <time_frame>Variable - minimum of 12 weeks of follow-up.</time_frame>
    <description>The proportion of patients who had a recurrence of the study ulcer during follow-up after achieving wound closure during the active treatment period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary Efficacy: Cumulative Proportion of Patients Completely Healed by the End of the Follow-up Period (24 Weeks).</measure>
    <time_frame>24 weeks</time_frame>
    <description>The proportion of patients achieving wound closure by the end of the study follow-up period, 90 days after the end of the active treatment period.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Leg Ulcer</condition>
  <condition>Varicose Ulcer</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Multi-layer compression bandaging (Profore)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Celaderm, Bi-Weekly</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Celaderm, bi-weekly applications, up to a maximum of four applications</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Celaderm, Weekly</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Celaderm, applied weekly, up to a maximum of four applications</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Celaderm (Frozen Cultured Epidermal Allograft)</intervention_name>
    <description>Four biweekly applications of Celaderm plus compression therapy</description>
    <arm_group_label>Celaderm, Bi-Weekly</arm_group_label>
    <other_name>Frozen Cultured Epidermal Allograft (CEA)</other_name>
    <other_name>Cultured Keratinocytes</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Celaderm (Frozen Cultured Epidermal Allograft)</intervention_name>
    <description>Four weekly applications of Celaderm plus compression therapy</description>
    <arm_group_label>Celaderm, Weekly</arm_group_label>
    <other_name>Frozen Cultured Epidermal Allograft (CEA)</other_name>
    <other_name>Cultured Keratinocytes</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Control (compression bandaging)</intervention_name>
    <description>Multi-layer compression bandaging</description>
    <arm_group_label>Control</arm_group_label>
    <other_name>Profore</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  venous ulcer &gt; 1 month and &lt; 12 months in duration; 2 to 20 sq cm in surface area; not
             infected

          -  confirmatory venous ultrasound showing prior DVT and concurrent venous reflux

          -  ankle-brachial index 0.80 or greater

        Exclusion Criteria:

          -  cutaneous malignancy

          -  recent treatment with corticosteroids or chemotherapeutic agents

          -  wound exposed bone, tendon or neurovascular structure

          -  wound infected and requiring antibiotics
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David E Eisenbud, MD</last_name>
    <role>Study Director</role>
    <affiliation>Shire Regenerative Medicine, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dr. Robert Snyder</name>
      <address>
        <city>Tamarac</city>
        <state>Florida</state>
        <zip>33321</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Center for Limb Preservation</name>
      <address>
        <city>Niles</city>
        <state>Illinois</state>
        <zip>60714</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center, Division of Podiatry</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Curative &amp; Palliative Wound Care, Calvary Hospital</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State University of New York Stony Brook</name>
      <address>
        <city>Stony Brook</city>
        <state>New York</state>
        <zip>11794</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of North Carolina at Chapel Hill, Division of Vascular Surgery</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Blair Medical Associates, Inc., Station Medical Center, Associates Wound Clinic</name>
      <address>
        <city>Altoona</city>
        <state>Pennsylvania</state>
        <zip>16602</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peripheral Vascular Associates, P.A.</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dixie Regional Medical Center, Wound Care</name>
      <address>
        <city>Saint George</city>
        <state>Utah</state>
        <zip>84770</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 10, 2006</study_first_submitted>
  <study_first_submitted_qc>November 13, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 14, 2006</study_first_posted>
  <results_first_submitted>March 18, 2013</results_first_submitted>
  <results_first_submitted_qc>March 18, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 16, 2013</results_first_posted>
  <last_update_submitted>August 9, 2013</last_update_submitted>
  <last_update_submitted_qc>August 9, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 21, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>wound</keyword>
  <keyword>leg</keyword>
  <keyword>venous</keyword>
  <keyword>chronic</keyword>
  <keyword>wound healing</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ulcer</mesh_term>
    <mesh_term>Leg Ulcer</mesh_term>
    <mesh_term>Varicose Ulcer</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>An enrollment of 55 patients was planned to produce an expected yield of approximately 45 evaluable patients at up to nine study centers.</recruitment_details>
      <pre_assignment_details>72 patients were consented in this study. Eighteen failed screening: eight had HbA1c &gt; 7%; six failed wound size criteria; one was positive for HIV; one had a normal venous ultrasound; and two withdrew consent.
Of the remaining 54 patients, 14 were not randomized: 11 healed &gt; 50% during screening; one had a severe AE; and two more withdrew.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Group I - Weekly Celaderm</title>
          <description>Weekly topical applications of Celaderm, up to a maximum of four (4) applications, in combination with Adaptic and Profore four-layer compression dressing</description>
        </group>
        <group group_id="P2">
          <title>Group II - Bi-weekly Celaderm</title>
          <description>Bi-weekly topical applications of Celaderm, up to a maximum of four (4) applications, in combination with Adaptic and Profore four-layer compression dressing</description>
        </group>
        <group group_id="P3">
          <title>Group III - Control</title>
          <description>Adaptic and Profore four-layer compression dressing</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="15"/>
                <participants group_id="P3" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="15"/>
                <participants group_id="P3" count="11">One patient withdrew: did not want to comply with study requirements</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Group I - Weekly Celaderm</title>
          <description>Weekly topical applications of Celaderm, up to a maximum of four (4) applications, in combination with Adaptic and Profore four-layer compression dressing</description>
        </group>
        <group group_id="B2">
          <title>Group II - Bi-weekly Celaderm</title>
          <description>Bi-weekly topical applications of Celaderm, up to a maximum of four (4) applications, in combination with Adaptic and Profore four-layer compression dressing</description>
        </group>
        <group group_id="B3">
          <title>Group III - Control</title>
          <description>Adaptic and Profore four-layer compression dressing</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="13"/>
            <count group_id="B2" value="15"/>
            <count group_id="B3" value="12"/>
            <count group_id="B4" value="40"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67.54" spread="12.65"/>
                    <measurement group_id="B2" value="60.40" spread="8.75"/>
                    <measurement group_id="B3" value="64" spread="12.85"/>
                    <measurement group_id="B4" value="65.28" spread="11.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Primary Efficacy: Cumulative Proportion of Patients Completely Healed by the End of the Treatment Period, as Judged by the Investigator’s Direct Observation.</title>
        <description>The primary efficacy observation was the proportion of wounds that achieved complete wound closure after 12 weeks of active treatment (i.e. of of Week 15 including screening/wash-in phase.)</description>
        <time_frame>12 weeks</time_frame>
        <population>Intent-to-Treat population (i.e. all subjects randomized to treatment)</population>
        <group_list>
          <group group_id="O1">
            <title>Group I - Weekly Celaderm</title>
            <description>Weekly topical applications of Celaderm, up to a maximum of four (4) applications, in combination with Adaptic and Profore four-layer compression dressing</description>
          </group>
          <group group_id="O2">
            <title>Group II - Bi-weekly Celaderm</title>
            <description>Bi-weekly topical applications of Celaderm, up to a maximum of four (4) applications, in combination with Adaptic and Profore four-layer compression dressing</description>
          </group>
          <group group_id="O3">
            <title>Group III - Control</title>
            <description>Adaptic and Profore four-layer compression dressing</description>
          </group>
        </group_list>
        <measure>
          <title>Primary Efficacy: Cumulative Proportion of Patients Completely Healed by the End of the Treatment Period, as Judged by the Investigator’s Direct Observation.</title>
          <description>The primary efficacy observation was the proportion of wounds that achieved complete wound closure after 12 weeks of active treatment (i.e. of of Week 15 including screening/wash-in phase.)</description>
          <population>Intent-to-Treat population (i.e. all subjects randomized to treatment)</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Secondary Efficacy: Proportion of Patients Achieving 90% Re-epithelialization After 12 Weeks of Active Treatment.</title>
        <description>Re-epithelialization was judged by the Medical Monitor based upon computerized planimetry of serial wound photographs.</description>
        <time_frame>12 Weeks</time_frame>
        <population>Intent-to-Treat population</population>
        <group_list>
          <group group_id="O1">
            <title>Group I - Weekly Celaderm</title>
            <description>Weekly topical applications of Celaderm, up to a maximum of four (4) applications, in combination with Adaptic and Profore four-layer compression dressing</description>
          </group>
          <group group_id="O2">
            <title>Group II - Bi-weekly Celaderm</title>
            <description>Bi-weekly topical applications of Celaderm, up to a maximum of four (4) applications, in combination with Adaptic and Profore four-layer compression dressing</description>
          </group>
          <group group_id="O3">
            <title>Group III - Control</title>
            <description>Adaptic and Profore four-layer compression dressing</description>
          </group>
        </group_list>
        <measure>
          <title>Secondary Efficacy: Proportion of Patients Achieving 90% Re-epithelialization After 12 Weeks of Active Treatment.</title>
          <description>Re-epithelialization was judged by the Medical Monitor based upon computerized planimetry of serial wound photographs.</description>
          <population>Intent-to-Treat population</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Secondary Efficacy: Durability of Wound Closure Through 12 Weeks After the End of the Treatment Period.</title>
        <description>The proportion of patients who had a recurrence of the study ulcer during follow-up after achieving wound closure during the active treatment period.</description>
        <time_frame>Variable - minimum of 12 weeks of follow-up.</time_frame>
        <population>Intent-to-treat population achieving primary outcome</population>
        <group_list>
          <group group_id="O1">
            <title>Group I - Weekly Celaderm</title>
            <description>Weekly topical applications of Celaderm, up to a maximum of four (4) applications, in combination with Adaptic and Profore four-layer compression dressing</description>
          </group>
          <group group_id="O2">
            <title>Group II - Bi-weekly Celaderm</title>
            <description>Bi-weekly topical applications of Celaderm, up to a maximum of four (4) applications, in combination with Adaptic and Profore four-layer compression dressing</description>
          </group>
          <group group_id="O3">
            <title>Group III - Control</title>
            <description>Adaptic and Profore four-layer compression dressing</description>
          </group>
        </group_list>
        <measure>
          <title>Secondary Efficacy: Durability of Wound Closure Through 12 Weeks After the End of the Treatment Period.</title>
          <description>The proportion of patients who had a recurrence of the study ulcer during follow-up after achieving wound closure during the active treatment period.</description>
          <population>Intent-to-treat population achieving primary outcome</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Secondary Efficacy: Cumulative Proportion of Patients Completely Healed by the End of the Follow-up Period (24 Weeks).</title>
        <description>The proportion of patients achieving wound closure by the end of the study follow-up period, 90 days after the end of the active treatment period.</description>
        <time_frame>24 weeks</time_frame>
        <population>Intent-to-Treat population</population>
        <group_list>
          <group group_id="O1">
            <title>Group I - Weekly Celaderm</title>
            <description>Weekly topical applications of Celaderm, up to a maximum of four (4) applications, in combination with Adaptic and Profore four-layer compression dressing</description>
          </group>
          <group group_id="O2">
            <title>Group II - Bi-weekly Celaderm</title>
            <description>Bi-weekly topical applications of Celaderm, up to a maximum of four (4) applications, in combination with Adaptic and Profore four-layer compression dressing</description>
          </group>
          <group group_id="O3">
            <title>Group III - Control</title>
            <description>Adaptic and Profore four-layer compression dressing</description>
          </group>
        </group_list>
        <measure>
          <title>Secondary Efficacy: Cumulative Proportion of Patients Completely Healed by the End of the Follow-up Period (24 Weeks).</title>
          <description>The proportion of patients achieving wound closure by the end of the study follow-up period, 90 days after the end of the active treatment period.</description>
          <population>Intent-to-Treat population</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Group I - Weekly Celaderm</title>
          <description>Weekly topical applications of Celaderm, up to a maximum of four (4) applications, in combination with Adaptic and Profore four-layer compression dressing</description>
        </group>
        <group group_id="E2">
          <title>Group II - Bi-weekly Celaderm</title>
          <description>Bi-weekly topical applications of Celaderm, up to a maximum of four (4) applications, in combination with Adaptic and Profore four-layer compression dressing</description>
        </group>
        <group group_id="E3">
          <title>Group III - Control</title>
          <description>Adaptic and Profore four-layer compression dressing</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Chest Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Swelling</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Siezure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Exacerbation of Chronic Asthma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Cellulitis</sub_title>
                <description>Cellulitis of the study or non-study leg</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Critical Limb Ischemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Ulcer Infection</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="13"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Limitations of the trial include the potential for outcome assessment bias as the study was not blinded.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Mollie Carter, MD, Medical Director</name_or_title>
      <organization>Shire Regenerative Medicine</organization>
      <phone>(858) 754-5678</phone>
      <email>mcarter@shire.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

